---
document_datetime: 2025-11-14 11:31:20
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ondexxya-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: ondexxya-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.4127594
conversion_datetime: 2025-12-31 07:38:29.634523
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Ondexxya

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                           |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|---------------------------------------------------|
| Variation type IB /  | This was an application for a group of | 14/11/2025                          |                                             | SmPC                             | To extend the shelf-life of the finished product, |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000304332          | variations. B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.1 As packaged for sale (supported by real time data) - Accepted B.II.f.1 Change in the shelf-life or storage conditions of the finished product - B.II.f.1.e Change to an approved stability protocol - Accepted                                                                                          |            |            |      | Ondexxya 200 mg, Powder for Solution for Infusion, as packaged for sale, from 48 months to 60 months when stored at the intended storage condition of 2 to 8Â°C.   |
|----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUR / EMA/PSUR/0000248508 | - - In view of available data on the interaction between andexanet alfa and heparin from case reports, and in view of a plausible mechanism of action, the PRAC agreed that the interaction between andexanet alfa and heparin should be supplemented with further examples. The PRAC concluded that the product information of products containing andexanet alfa should be amended accordingly. | 19/06/2025 | 21/08/2025 | SmPC | Variation                                                                                                                                                         |